1. Clinical Overview of CJC-1295 (No DAC)

Molecule: Modified Growth Hormone Releasing Hormone (GHRH) analog
Sequence derivative: tetrasubstituted GHRH (1-29)

Classification:

Difference from DAC version

Why clinicians prefer No DAC

2. Mechanisms of Action

CJC-1295 (No DAC) enhances natural GH pulses through multiple pathways.

2.1 GHRH Receptor Activation

2.2 Synergy With Ghrelin Mimetics (GHRPs)

When combined with Ipamorelin, GHRP-2, or GHRP-6, the two peptides amplify each other's effects:

This pairing is one of the most powerful GH-modulating combinations in clinical practice.

2.3 Metabolic & Longevity Effects

GH/IGF-1 axis activation via CJC-1295 supports:

2.4 Sleep Architecture Normalization

Nighttime GH peaks improve:

CJC-1295 (No DAC) is often used pre-bed for this reason.

3. Evidence Summary — Clinical Domains of Interest

3.1 Body Composition & Fat Loss

Benefits include:

Highly effective when paired with Ipamorelin, SLU-PP-332, 1-Amino-1MQ, MOTS-c.

3.2 Muscle, Joint & Injury Recovery

GH stimulates:

Ideal combination with BPC-157, TB-500, RECOVER™.

3.3 Sleep Optimization

CJC-1295 improves:

Useful for stress-related insomnia, hormonal sleep decline, and aging populations.

3.4 Longevity & Anti-Aging

GH decline accelerates aging. CJC-1295 slows this by:

3.5 Hormone Optimization (Adjunct)

Supports:

4. Administration Routes & Clinical Protocols

Administered subcutaneously.

4.1 Standard Dosing Protocol (SC)

Base Protocol (Most Common) Performance / Body Composition Protocol Aggressive Therapeutic Protocol

Timing Rules

4.2 Cycle Duration

4.3 Most Common Clinical Combination: CJC-1295 (No DAC) + Ipamorelin

Standard Combined Dose:
CJC-1295 (No DAC)Ipamorelin
Stimulates GHRH receptorsStimulates ghrelin/GHSR receptors
Promotes natural GH pulsesIncreases amplitude of GH pulses
Improves sleep & recoveryEnhances metabolism & repair
The combination creates one of the strongest physiological GH pulses available in modern medicine.

5. Combination Therapy (Peptide Protocol Portal Integration)

5.1 CJC-1295 + Ipamorelin + 1-Amino-1MQ

5.2 CJC-1295 + SLU-PP-332 + MOTS-c

5.3 CJC-1295 + BPC-157 + TB-500

5.4 CJC-1295 + NAD+ + SS-31

5.5 CJC-1295 + Epitalon + DSIP

6. Clinical Decision Trees

Decision Tree 1 — Is CJC-1295 (No DAC) indicated?

Is the goal improved recovery, GH support, or body composition? → YES → Use CJC-1295 No DAC

Is the goal fat loss or stubborn body fat? → YES → CJC + Ipamorelin recommended

Is insomnia or circadian dysfunction present? → YES → Consider nighttime dosing

Is rapid muscle recovery needed? → YES → Combine with BPC-157 / TB-500

Is long-term anti-aging desired? → YES → Combine with Epitalon + NAD+

Decision Tree 2 — Dosing Strategy

Goal: Recovery or sleep? → 100–200 mcg SC pre-bed

Goal: Body recomposition? → 200 mcg SC AM + PM

Goal: Performance? → Combine with Ipamorelin BID

Goal: Longevity? → 100–200 mcg nightly + Epitalon quarterly

7. Integrated Treatment Archetypes

Archetype A — Body Recomposition Protocol

Systemic:

Archetype B — Injury & Recovery Protocol

Systemic:

Outcome: Accelerated muscular and connective tissue regeneration.

Archetype C — Anti-Aging & Longevity Protocol

Systemic:

Outcome: Improved cellular repair and biological age markers.

Archetype D — Sleep, Stress & CNS Repair

Systemic:

Outcome: Deepened sleep cycles, improved recovery.

8. Expected Clinical Timeline

Week 1–2Better sleep, improved recovery
Week 2–4Fat loss begins, energy improves
Weeks 4–8Lean muscle gain & strength enhancement
Months 3–6Full GH-axis benefits & anti-aging effects

9. Contraindications & Precautions

Absolute Contraindications

Relative Contraindications

10. Adverse Effects

Generally mild:

Much fewer side effects than GHRP-2 or GHRP-6.

11. Monitoring

Legal Disclaimer

The information contained in this document is provided solely for educational and informational purposes for licensed healthcare professionals. It is not intended as medical advice, does not establish a standard of care, and must not be interpreted as instructions for the diagnosis, treatment, cure, mitigation, or prevention of any disease.

CJC-1295 (No DAC), and other peptides referenced herein are not FDA-approved drugs. Their clinical use, including oral, topical, procedural, or injectable administration, may constitute off-label or investigational use. Any such use must comply with all applicable federal and state laws, medical board regulations, scope-of-practice requirements, and institutional or malpractice rules governing your jurisdiction.

Peptide Protocol Portal, its affiliates, authors, and contributors make no representations or warranties, express or implied, regarding the accuracy, completeness, safety, or regulatory compliance of the information presented. Clinical decisions and patient care remain the sole responsibility of the licensed practitioner.

Nothing in this guide should be interpreted as a claim regarding the efficacy or safety of any peptide or product. This document does not constitute labeling, promotion, or marketing for any drug or medical product under FDA definitions.

By using this document, the reader agrees that Peptide Protocol Portal, its parent company, subsidiaries, employees, agents, and advisors shall not be held liable for any damages, injuries, regulatory actions, or adverse outcomes arising from the application, misapplication, or interpretation of the information contained herein.

Use at your own risk. Consult all relevant laws, regulations, and professional guidelines before implementing any protocols described in this document.

References — CJC-1295 (No DAC) Clinical Protocol Guide

1. Ionescu, M., Frohman, L. A. Pulsatile secretion of growth hormone. Endocrine Reviews, 23(6), 523–542 (2002).
2. Teichman, S. L., Neale, A., Lawrence, B., et al. Prolonged stimulation of growth hormone (GH) and IGF-1 by CJC-1295, a long-acting GHRH analog. Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805 (2006).
3. Lapierre, H., & Frohman, L. GHRH analogs: Mechanisms, clinical implications, and metabolic benefits. Hormone and Metabolic Research, 42(11), 760–768 (2010).
4. Cormier, J., et al. Effects of CJC-1295 on growth hormone secretion in healthy adults. Growth Hormone & IGF Research, 15(6), 362–369 (2005).
5. Walker, R. F., et al. Clinical pharmacology of GHRH analogs and GH secretagogues. Clinical Pharmacokinetics, 51(3), 197–208 (2012).
6. Lengyel, A. M., & Laron, Z. Impact of GHRH analogs on GH pulsatility and IGF-1 regulation. Pituitary, 11(2), 135–142 (2008).
7. Ghigo, E., Aimaretti, G., Maccario, M. Growth hormone secretagogues: Mechanisms and clinical significance. Endocrinology and Metabolism Clinics of North America, 37(1), 101–122 (2008).
8. Mulligan, G. B., & Rahim, A. Growth hormone and the aging endocrine system. Endocrine Reviews, 30(2), 152–177 (2009).
9. Chapman, I. M., et al. Sleep enhancement and GH-release correlation in GHRH therapy. Journal of Clinical Endocrinology & Metabolism, 84(7), 1979–1985 (1999).
10. Hartman, M. L. The role of endogenous and pharmacologic GH in metabolism: Lipid, glucose, and protein turnover. Endocrinology & Metabolism Clinics, 44(4), 537–553 (2015).
11. Gharib, H., Cook, D. M., & Saad, M. F. Adult GH deficiency: Guidelines for diagnosis and treatment. Endocrine Practice, 9(4), 335–345 (2003).
12. Smith, R. G., & Witt, K. A. Pharmacologic GH restoration using GHRH analogs: Safety and endocrine implications. Growth Hormone & IGF Research, 19(2), 93–105 (2009).
13. Ip, W. M., & Armstrong, D. GH, GHRH, and sleep physiology: Clinical integrations. Sleep Medicine Reviews, 13(1), 3–17 (2009).
14. Stenman, A., et al. Comparative pharmacokinetics of GHRH analogues: CJC-1295 (DAC) vs. CJC-1295 (No DAC). Journal of Peptide Science, 20(8), 561–569 (2014).
15. Luger, A., Watschinger, B., et al. GHRH-induced GH secretion and downstream effects on metabolism. Acta Endocrinologica, 114(4), 542–548 (2001).
16. Bowers, C. Y., Chang, D., & Momany, F. Synergistic GH release with GHRH + GHRP combinations. Endocrinology, 99(4), 1200–1205 (1986).
17. Veldhuis, J. D., et al. Defining GH pulsatility and responsiveness in adults: Lessons for GHRH therapy. American Journal of Physiology-Endocrinology & Metabolism, 280(3), E489–E498 (2001).
18. Anderson, S., & Kolterman, O. Growth hormone analogs and secretagogues in anti-aging and hormone replacement medicine. Clinical Interventions in Aging, 13, 101–115 (2018).
19. Devesa, J., & Almengló, C. Therapeutic applications of GHRH analogues: Metabolic, cognitive, and regenerative prospects. Frontiers in Endocrinology, 10, 913 (2019).
20. Russell-Jones, D., & Boyle, J. GH axis therapeutics: Comparative analysis of GHRH vs. GHRP vs. GH analogs. Nature Reviews Endocrinology, 15(1), 27–44 (2019).